Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Inv. presentation
Appointed director
Director comp.
Acq. announced
Director departure

RHYTHM PHARMACEUTICALS, INC. (RYTM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Other Events  Interactive Data
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "David P. Meeker, M.D.",
"Employment",
"Employment"
08/01/2023 8-K Quarterly results
05/02/2023 8-K Quarterly results
Docs: "Three months ended March 31, 2023 2022 Revenues: Product revenue, net $ 11,469 $ 1,498 Costs and expenses: Cost of sales 1,421 230 Research and development 37,945 32,510 Selling, general, and administrative 24,634 21,449 Total costs and expenses 64,000 54,189 Loss from operations Other income: Other expense, net Interest expense — Interest income 3,440 160 Total other income , net 352 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 56,708,975 50,326,627 Other comprehensive loss: Net loss $ $ Foreign currency translation adjustment 21 — Unrealized gain , net on marketable securities 65 Comprehensive loss $ $ Condensed Consolidated Balance Sheets"
03/01/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "5 0 0 4 8 12 16 20 24 28 32 36 40 44 BMI"
11/08/2022 8-K Quarterly results
Docs: "Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update"
11/03/2022 8-K Quarterly results
09/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as representatives of the underwriters named therein",
"Opinion of Latham & Watkins LLP"
08/02/2022 8-K Quarterly results
Docs: "Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update"
06/16/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
04/06/2022 8-K Investor presentation
Docs: "MSH MC4R POMC SRC1 SH2B1 PCSK1 ALMS1"
03/01/2022 8-K Quarterly results
12/08/2021 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "Investor Contact:"
09/02/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "Investor Contact:"
06/14/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
01/04/2021 8-K/A Quarterly results
12/11/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Bylaws of Rhythm Pharmaceuticals, Inc"
11/02/2020 8-K Quarterly results
Docs: "Rhythm Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 22,995 $ 26,572 $ 68,496 $ 84,641 Selling, general, and administrative 11,289 10,535 33,006 27,135 Total operating expenses 34,284 37,107 101,502 111,776 Loss from operations Other income : Interest income, net 466 1,104 2,403 4,003 Total other income, net 466 1,104 2,403 4,003 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average common shares outstanding, basic and diluted 44,142,334 34,541,765 44,097,178 34,470,995 Other comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities — 238 — Comprehensive loss $ $ $ ..."
09/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy